Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Prostate Cancer Research Today


View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications

Volume 6 (2009), Issue 7 (July)

  1. Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.
    Br J Cancer, 101(1): 185-91. [Abstract] [Full-text]
  2. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.
    Br J Cancer, 101(1): 19-26. [Abstract] [Full-text]
  3. Racial differences in risk of prostate cancer associated with metabolic syndrome.
    Urology, 74(1): 185-90. [Abstract] [Full-text]
  4. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Urology, 74(1): 177-83. [Abstract] [Full-text]
  5. Prevalence of erectile dysfunction in men screened for prostate cancer.
    Urology, 74(1): 89-93. [Abstract] [Full-text]
  6. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?
    Urology, 74(1): 167-70. [Abstract] [Full-text]
  7. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
    Urology, 74(1): 171-6. [Abstract] [Full-text]
  8. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis.
    Carcinogenesis, 30(7): 1125-31. [Abstract] [Full-text]
  9. Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.
    Carcinogenesis, 30(7): 1082-8. [Abstract] [Full-text]
  10. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.
    Cancer Res, 69(13): 5601-9. [Abstract] [Full-text]
  11. Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
    Cancer Res, 69(13): 5568-74. [Abstract] [Full-text]
  12. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status.
    Biochem Pharmacol, 78(5): 469-76. [Abstract] [Full-text]
  13. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.
    Endocrine, 36(1): 87-97. [Abstract] [Full-text]
  14. Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer.
    Med Care Res Rev, 66(4): 409-35. [Abstract] [Full-text]
  15. Screening for prostate cancer.
    CA Cancer J Clin, 59(4): 264-73. [Abstract] [Full-text]
  16. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
    Med Hypotheses, 73(3): 387-8. [Abstract] [Full-text]
  17. Expression of the Bcl-2 protein BAD promotes prostate cancer growth.
    PLoS One, 4(7): e6224. [Abstract] [Full-text]
  18. Neuroendocrine differentiation of LNCaP cells suggests: VDAC in the cell membrane is involved in the extrinsic apoptotic pathway.
    Mol Genet Metab, 97(4): 241-3. [Abstract] [Full-text]
  19. A comparison of prone three-dimensional conformal radiotherapy with supine intensity-modulated radiotherapy for prostate cancer: which technique is more effective for rectal sparing?
    Br J Radiol, 82(980): 654-61. [Abstract] [Full-text]
  20. Characterization of preclinical models of prostate cancer using PET-based molecular imaging.
    Eur J Nucl Med Mol Imaging, 36(8): 1245-55. [Abstract] [Full-text]
  21. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells.
    Cancer Genet Cytogenet, 192(2): 60-7. [Abstract] [Full-text]
  22. DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness.
    J Urol, 182(2): 756-61. [Abstract] [Full-text]
  23. Duplicate presentations on prostate cancer at American Urological Association and European Association of Urology annual meetings.
    J Urol, 182(2): 674-8; discussion 678-9. [Abstract] [Full-text]
  24. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    J Urol, 182(2): 517-25; discussion 525-7. [Abstract] [Full-text]
  25. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
    J Urol, 182(2): 485-90; discussion 490. [Abstract] [Full-text]
  26. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    J Urol, 182(2): 491-6; discussion 496-8. [Abstract] [Full-text]
  27. Chemoprevention of prostate cancer.
    J Urol, 182(2): 499-507; discussion 508. [Abstract] [Full-text]
  28. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    J Urol, 182(2): 509-15; discussion 515-6. [Abstract] [Full-text]
  29. The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese.
    J Surg Oncol, 100(2): 106-10. [Abstract] [Full-text]
  30. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
    Nucleic Acids Res, 37(12): 4135-48. [Abstract] [Full-text]
  31. Dural metastasis from prostatic adenocarcinoma mimicking chronic subdural hematoma.
    J Clin Neurosci, 16(8): 1084-6. [Abstract] [Full-text]
  32. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
    J Pathol, 218(4): 505-13. [Abstract] [Full-text]
  33. Oxidative stress in prostate cancer.
    Cancer Lett, 282(2): 125-36. [Abstract] [Full-text]
  34. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
    Br J Cancer, 101(2): 263-8. [Abstract] [Full-text]
  35. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.
    Bioorg Med Chem, 17(14): 4888-93. [Abstract] [Full-text]
  36. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer.
    J Pineal Res, 47(1): 8-14. [Abstract] [Full-text]
  37. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
    Am J Clin Pathol, 132(2): 211-20; quiz 307. [Abstract] [Full-text]
  38. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.
    Clin Cancer Res, 15(14): 4694-9. [Abstract] [Full-text]
  39. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Clin Cancer Res, 15(14): 4706-11. [Abstract] [Full-text]
  40. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Cancer Res, 69(14): 5893-900. [Abstract] [Full-text]
  41. A brainstem paraneoplastic syndrome associated with prostate cancer.
    J Neurol Neurosurg Psychiatry, 80(8): 934-5. [Abstract] [Full-text]
  42. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.
    J Clin Oncol, 27(21): 3547-56. [Abstract] [Full-text]
  43. Antibody-specific detection of CAIX in breast and prostate cancers.
    Biochem Biophys Res Commun, 386(3): 488-92. [Abstract] [Full-text]
  44. Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score.
    Med Image Anal, 13(4): 609-20. [Abstract] [Full-text]
  45. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
    J Clin Oncol, 27(21): 3459-64. [Abstract] [Full-text]
  46. Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(5): 1609-16. [Abstract] [Full-text]
  47. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.
    Int J Radiat Oncol Biol Phys, 74(5): 1405-18. [Abstract] [Full-text]
  48. Effect of translational and rotational errors on complex dose distributions with off-line and on-line position verification.
    Int J Radiat Oncol Biol Phys, 74(5): 1600-8. [Abstract] [Full-text]
  49. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
    Int J Radiat Oncol Biol Phys, 74(5): 1441-6. [Abstract] [Full-text]
  50. Internal audit of a comprehensive IMRT program for prostate cancer: a model for centers in developing countries?
    Int J Radiat Oncol Biol Phys, 74(5): 1447-54. [Abstract] [Full-text]
  51. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy.
    Int J Radiat Oncol Biol Phys, 74(5): 1431-40. [Abstract] [Full-text]
  52. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 74(5): 1424-30. [Abstract] [Full-text]
  53. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Int J Radiat Oncol Biol Phys, 74(5): 1419-23. [Abstract] [Full-text]
  54. Insomnia, depression, and distress among outpatients with prostate cancer.
    Appl Nurs Res, 22(3): 154-8. [Abstract] [Full-text]
  55. Risk factors, prevention and early detection of prostate cancer.
    Prim Care, 36(3): 603-21. [Abstract] [Full-text]
  56. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Anal Biochem, 392(2): 117-25. [Abstract] [Full-text]
  57. Expression, regulation and function of the ISGylation system in prostate cancer.
    Oncogene, 28(28): 2606-20. [Abstract] [Full-text]
  58. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    BJU Int, 104(3): 310-4. [Abstract] [Full-text]
  59. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
    BJU Int, 104(3): 304-9. [Abstract] [Full-text]
  60. Is farm-related job title an adequate surrogate for pesticide exposure in occupational cancer epidemiology?
    Occup Environ Med, 66(8): 497-501. [Abstract] [Full-text]
  61. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
    BJU Int, 104(3): 321-5. [Abstract] [Full-text]
  62. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy.
    BJU Int, 104(3): 315-20. [Abstract] [Full-text]
  63. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.
    Int J Cancer, 125(6): 1372-9. [Abstract] [Full-text]
  64. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis.
    Int J Cancer, 125(6): 1414-23. [Abstract] [Full-text]
  65. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
    Int J Cancer, 125(5): 1143-6. [Abstract] [Full-text]
  66. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.
    Cancer Lett, 283(1): 29-35. [Abstract] [Full-text]
  67. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
    Proc Natl Acad Sci U S A, 106(29): 12178-83. [Abstract] [Full-text]
  68. Prostate cancer regulatory networks.
    J Cell Biochem, 107(5): 845-52. [Abstract] [Full-text]
  69. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.
    J Cell Biochem, 107(5): 992-1001. [Abstract] [Full-text]
  70. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
    Prostate, 69(12): 1334-42. [Abstract] [Full-text]
  71. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells.
    Prostate, 69(12): 1343-52. [Abstract] [Full-text]
  72. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
    Prostate, 69(12): 1270-80. [Abstract] [Full-text]
  73. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.
    Prostate, 69(12): 1325-33. [Abstract] [Full-text]
  74. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
    Prostate, 69(12): 1303-11. [Abstract] [Full-text]
  75. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Prostate, 69(12): 1292-302. [Abstract] [Full-text]
  76. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
    Prostate, 69(12): 1257-69. [Abstract] [Full-text]
  77. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.
    Prostate, 69(12): 1281-91. [Abstract] [Full-text]
  78. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
    Prostate, 69(12): 1312-24. [Abstract] [Full-text]
  79. The Del1 deposition domain can immobilize 3alpha-hydroxysteroid dehydrogenase in the extracellular matrix without interfering with enzymatic activity.
    Bioprocess Biosyst Eng, 32(5): 569-73. [Abstract] [Full-text]
  80. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
    Cell, 138(2): 245-56. [Abstract] [Full-text]
  81. NF-kappaB regulates androgen receptor expression and prostate cancer growth.
    Am J Pathol, 175(2): 489-99. [Abstract] [Full-text]
  82. Suppressive roles of calreticulin in prostate cancer growth and metastasis.
    Am J Pathol, 175(2): 882-90. [Abstract] [Full-text]
  83. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Cancer, 115(15): 3437-45. [Abstract] [Full-text]
  84. Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging.
    Exp Biol Med (Maywood), 234(8): 860-79. [Abstract] [Full-text]
  85. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
    Cancer, 115(15): 3446-56. [Abstract] [Full-text]
  86. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Cancer, 115(15): 3468-74. [Abstract] [Full-text]
  87. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
    Comput Methods Programs Biomed, 96(1): 33-41. [Abstract] [Full-text]
  88. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach.
    Cancer Invest, 27(7): 794-801. [Abstract] [Full-text]
  89. Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians.
    PLoS One, 4(7): e6370. [Abstract] [Full-text]
  90. Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population.
    BMC Urol, 9: 7. [Abstract] [Full-text]
  91. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study.
    Br J Cancer, 101(3): 390-4. [Abstract] [Full-text]
  92. Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer, 101(3): 522-5. [Abstract] [Full-text]
  93. An improved method for constructing tissue microarrays from prostate needle biopsy specimens.
    J Clin Pathol, 62(8): 694-8. [Abstract] [Full-text]
  94. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
    J Magn Reson Imaging, 30(2): 327-34. [Abstract] [Full-text]
  95. Combined T2-weighted and diffusion-weighted MRI for diagnosis of urinary bladder invasion in patients with prostate carcinoma.
    J Magn Reson Imaging, 30(2): 351-6. [Abstract] [Full-text]
  96. Characterization of response to radiation mediated gene therapy by means of multimodality imaging.
    Magn Reson Med, 62(2): 348-56. [Abstract] [Full-text]
  97. Passing through the wall: on outings, exodus, angels, and the ark.
    J Relig Health, 48(3): 381-90. [Abstract] [Full-text]
  98. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
    Oncogene, 28(30): 2756-65. [Abstract] [Full-text]
  99. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
    Urol Int, 83(1): 122-4. [Abstract] [Full-text]
  100. Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms.
    Urol Int, 83(1): 60-5. [Abstract] [Full-text]
  101. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men.
    Carcinogenesis, 30(8): 1372-9. [Abstract] [Full-text]
  102. Novel single nucleotide polymorphism associations with colorectal cancer on chromosome 8q24 in African and European Americans.
    Carcinogenesis, 30(8): 1353-7. [Abstract] [Full-text]
  103. Health-related quality of life using SF-8 and EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy.
    Jpn J Clin Oncol, 39(8): 502-8. [Abstract] [Full-text]
  104. Cytokine genetic polymorphisms and prostate cancer aggressiveness.
    Carcinogenesis, 30(8): 1358-62. [Abstract] [Full-text]
  105. Putative health risks associated with vasectomy.
    Urol Clin North Am, 36(3): 337-45. [Abstract] [Full-text]
  106. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.
    Cancer Res, 69(15): 6042-8. [Abstract] [Full-text]
  107. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
    Cancer Res, 69(15): 6256-64. [Abstract] [Full-text]
  108. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
    Cancer Res, 69(15): 6027-32. [Abstract] [Full-text]
  109. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells.
    Biochem Biophys Res Commun, 387(1): 196-201. [Abstract] [Full-text]
  110. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Nucl Med Commun, 30(9): 693-9. [Abstract] [Full-text]
  111. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
    J Clin Oncol, 27(22): 3577-83. [Abstract] [Full-text]
  112. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    J Clin Oncol, 27(22): 3591-7. [Abstract] [Full-text]
  113. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
    Mod Pathol, 22(8): 1083-93. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.

Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)

Prostate Cancer Books

Prostate Cancer From A to Z

Prostate Cancer From A to Z